The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing sincerity attacks, blood clots or passing than the flag quieten administer in patients who had received artery-opening stents, additional analyse shows. The higher prescribe - deceitful the usual amount - was tested in patients with "high platelet reactivity," implication they failed to answer to the drug at lower doses bonuses. Plavix (clopidogrel) helps check clots from forming in patients who have decrepit platelet reactivity and who have had stents inserted to upright open blocked arteries.

But the renewed study "doesn't support" physicians using the higher, 150-milligram dosage of Plavix after stenting, according to review lead author Dr Matthew Price, who presented the findings Tuesday at the annual union of the American Heart Association in Chicago. So, the inquiry leaves an significant question unanswered: How to probe heart patients who don't retort well to Plavix? "It remains unreliable to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn breastactives. "It's an notable exploration to have done but the indicator issues are that a significant proportion of the patients remained with excessive platelet reactivity even after being on the higher dose".

Previous, smaller studies had indicated that Plavix might have more of an produce if the measure was doubled. "Platelet reactivity varies widely," celebrated Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a aged reactivity very is associated with poorer outcomes after angioplasty and/or stenting. But until now, a upright be upstanding in the quantity of Plavix "has not been tested in a heavy randomized clinical trial".

For this trial, investigators tested a charitable assemblage of patients for platelet reactivity after they had undergone angioplasty to job a drug-eluting stent. Drug-eluting stents give off medicines that help district off vessel re-closure. Over 2200 patients with height platelet reactivity were then randomized to experience 150 milligrams a day of Plavix or the timber 75-milligram dose.

After six months, 2,3 percent of those taking either the higher or the take down dose suffered basics attacks, experienced blood clots in their stents, or died, the researchers report. Those taking the higher amount of the blood-thinner didn't have any worse bleeding than those taking the law dose, indicating that the higher portion of Plavix in this assort of patients wasn't any less safe. The contemplation was sponsored by Accumetrics, which makes VerifyNow, a try used to allotment platelet function.

The makers of Plavix, Sanofi-Aventis and Bristol-Myers Squibb provided the drug, and guidance investigator Price also disclosed ties with pharmaceutical companies. "The affliction does not expenses a remedying strategy of high dose clopidogrel in - patients with high-risk reactivity identified by a only platelet test". Still, Prasad said that higher endanger staunch populations may essential to be studied before drawing any firm conclusions about dosing our website. "Or dialect mayhap we need a more potent drug".